Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b
Aclaris Therapeutics reported early positive signals for ATI-052 in Phase 1b trials treating eczema and asthma with good tolerance.· summarised by Stockedin
ACRS
Back to marketsAdd to watchlist Oct 28, 2025 · 2.39 USDOct 28, 2026 · 3.81 USD
Aclaris Therapeutics, Inc.
ACRS · NasdaqGS
$3.81+0.40%(+0.02)
Yahoo Finance · delay unknown · USD · just in
Price history
Yahoo Finance · delay unknown · USD · 5 h old
Key figures
- Previous close
- 3.79
- Day range
- 3.66 – 3.84
- Volume
- 1.4M
- Market cap
- —
Information, not investment advice.
News about Aclaris Therapeutics, Inc.
Finnhub · delay unknown · 12 h old
Headline and publisher summary only; full articles stay with the source.